Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia

European Journal of Clinical Investigation
M S WeintraubJ L Breslow

Abstract

Drugs that inhibit cholesterol synthesis have recently been released for lowering LDL-cholesterol levels. The current study examines the effect of one of these drugs, lovastatin, alone and in combination with cholestyramine on postprandial fat metabolism in five patients with severely elevated LDL-cholesterol and normal triglyceride levels (less than 1.8 mmol l-1) and in five patients with similarly elevated LDL-cholesterol and mildly elevated triglyceride levels (1.8 to 2.7 mmol l-1). In the group of patients with normal triglyceride levels, neither lovastatin alone nor in combination with cholestyramine had any effect on postprandial lipoprotein levels, while profoundly decreasing LDL-cholesterol levels. This provides evidence that LDL and postprandial lipoproteins are cleared by different mechanisms. In the group of five patients with mildly elevated triglyceride levels, in addition to LDL-cholesterol lowering, lovastatin significantly lowered VLDL-cholesterol, fasting triglyceride and postprandial lipoprotein levels. Thus in patients with mild hypertriglyceridaemia, lovastatin may have another favourable effect on the lipoprotein system in addition to LDL-cholesterol lowering.

References

Feb 1, 1975·Annals of Internal Medicine·J MorganrothD S Fredrickson
May 1, 1976·The American Journal of Clinical Nutrition·J M OlefskyG M Reaven
Nov 1, 1976·Metabolism: Clinical and Experimental·S M Grundy, H Y Mok
Sep 1, 1979·Circulation·D B Zilversmit
Jul 1, 1978·Archives of Disease in Childhood·C M Drillien
May 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·U BeisiegelR W Mahley
Jul 7, 1988·The New England Journal of Medicine·S M Grundy
Dec 1, 1987·The Journal of Clinical Investigation·M S WeintraubJ L Breslow
Nov 1, 1981·The Journal of Clinical Investigation·R W MahleyK H Weisgraber
Jun 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·T KitaR J Havel
Dec 1, 1984·The Journal of Clinical Investigation·J R PatschG Bengtsson-Olivecrona
Dec 1, 1984·The Journal of Clinical Investigation·D R Illingworth, G J Sexton
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Feb 1, 1983·The American Journal of Clinical Nutrition·M L KashyapR L Jackson
Jan 1, 1983·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J P KaneR J Havel
Aug 5, 1982·The New England Journal of Medicine·P J NestelM H Tan
May 1, 1964·The Journal of Clinical Investigation·P J NESTEL

❮ Previous
Next ❯

Citations

Apr 1, 1994·Atherosclerosis·H Gylling, T A Miettinen
Jan 1, 1995·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A CorsiniA L Catapano
Jun 5, 2002·Atherosclerosis. Supplements·Fredrik Karpe
Jun 20, 2001·Diabetes, Obesity & Metabolism·J R Burnett, G F Watts
Jul 1, 1997·The Proceedings of the Nutrition Society·C J Packard
Jan 14, 1999·Critical Reviews in Clinical Laboratory Sciences·P W Connelly, R A Hegele
Apr 25, 2000·Metabolism: Clinical and Experimental·H RelasT A Miettinen
Apr 3, 2003·Journal of Lipid Research·Klaus G ParhoferP Hugh R Barrett
May 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·R A HegeleP W Connelly
Apr 26, 2007·European Journal of Clinical Nutrition·D LaironC Williams
Jan 1, 1995·Scandinavian Journal of Gastroenterology·H Vanhanen, T A Miettinen
Nov 30, 2000·The Journal of Clinical Endocrinology and Metabolism·K G ParhoferP Schwandt
Jul 1, 1995·Metabolism: Clinical and Experimental·J W AndersonP R Oeltgen

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.